Abstract
Purpose: The purpose of the study is to evaluate the safety and efficacy of adjunctive use of mitomycin-C (MMC) using two different concentrations 0.2 mg/ml and 0.4 mg/ml for lacrimal duct probing to treat the nasolacrimal duct obstruction (NLDO) in adults. Subjects and methods: Prospective, an interventional comparative randomized pilot study of lacrimal duct probing conducted in the two study groups 0.02% MMC group (n = 30) and 0.04% MMC group (n = 30) in confirmed primary acquired NLDO of <1-year duration. Patency of lacrimal duct probing confirmed by syringing was compared at 1, 3, and 6-month follow-up in the two study groups, and corresponding subjective improvement of watering was appraised according to Kraft and Crawford grading. Results: Patency of lacrimal duct probing in 0.02% MMC versus 0.04% MMC group was 66.66%/73.33% (P = 0.71) at 1 month, 46.66%/66.66% (P = 0.09) at 3 months and 46.66%/66.66% (P = 0.03) at 6-month follow-up, respectively. Subjective improvement of watering (no watering and mild watering) observed in 0.02% MMC versus 0.04% MMC group was 46.66%/73.33% (P = 0.03), at 1 month, 66.66%/83.33% (P = 0.13) at 3 months and 56.66%/73.33% (P = 0.17) at 6-month follow-up. Conclusion: Adult lacrimal duct probing with 0.04% MMC was associated with significant higher objective success rate than adult lacrimal duct probing with 0.02% MMC, without added concurrently side effects.
Keywords
Publication details
- DOI
- 10.4103/ojo.ojo_33_21
- Journal
- Oman Journal of Ophthalmology, 15(1), 56-60
- Publisher
- Medknow Publications
- Open access
- Gold open access
Cite this article
APA 7
Saini, M., Bajaj, M. S., Pushker, N., Meel, R., Saini, K., Chaurasia, S., & Mehta, A. (2022). Evaluation of lacrimal duct probing in adults with 0.02% and 0.04% mitomycin-C in primary acquired nasolacrimal duct obstruction: A randomized comparative pilot study. Oman Journal of Ophthalmology, 15(1), 56-60. https://doi.org/10.4103/ojo.ojo_33_21
MLA 9
Saini, Manu, et al. "Evaluation of lacrimal duct probing in adults with 0.02% and 0.04% mitomycin-C in primary acquired nasolacrimal duct obstruction: A randomized comparative pilot study." Oman Journal of Ophthalmology, vol. 15, no. 1, 2022, pp. 56-60. https://doi.org/10.4103/ojo.ojo_33_21.
Chicago (author–date)
Saini, Manu, Mandeep Singh Bajaj, Neelam Pushker, Rachna Meel, Kulbhushan Saini, Shweta Chaurasia, and Aditi Mehta. 2022. "Evaluation of lacrimal duct probing in adults with 0.02% and 0.04% mitomycin-C in primary acquired nasolacrimal duct obstruction: A randomized comparative pilot study." Oman Journal of Ophthalmology 15 (1): 56-60. https://doi.org/10.4103/ojo.ojo_33_21.
Harvard
Saini, M., Bajaj, M. S., Pushker, N., Meel, R., Saini, K., Chaurasia, S. and Mehta, A. (2022) 'Evaluation of lacrimal duct probing in adults with 0.02% and 0.04% mitomycin-C in primary acquired nasolacrimal duct obstruction: A randomized comparative pilot study', Oman Journal of Ophthalmology, 15(1), pp. 56-60. doi:10.4103/ojo.ojo_33_21.
Vancouver
Saini M, Bajaj MS, Pushker N, Meel R, Saini K, Chaurasia S, et al. Evaluation of lacrimal duct probing in adults with 0.02% and 0.04% mitomycin-C in primary acquired nasolacrimal duct obstruction: A randomized comparative pilot study. Oman Journal of Ophthalmology. 2022;15(1):56-60. doi:10.4103/ojo.ojo_33_21
IEEE
M. Saini, M. S. Bajaj, N. Pushker, R. Meel, K. Saini, S. Chaurasia, and A. Mehta, "Evaluation of lacrimal duct probing in adults with 0.02% and 0.04% mitomycin-C in primary acquired nasolacrimal duct obstruction: A randomized comparative pilot study," Oman Journal of Ophthalmology, vol. 15, no. 1, pp. 56-60, 2022, doi: 10.4103/ojo.ojo_33_21.